Response,Percentage_of_R&D_investments
Pre-human/pre-clinical,16.4
Clinical_trials,49.2
Phase_I,9.7
Phase_II,10.6
Phase_III,28.9
Approval,3.3
Pharmacovigiliance_(Phase_IV),11.6
Uncategorized,19.4
